This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Glaxosmithkline Intellectual Property Development Limited. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Zoe Alicia Henley: Innovator in Kinase Inhibition
Introduction
Zoe Alicia Henley is a prominent inventor based in Stevenage, GB. She has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that inhibit kinase activity. Her work is crucial in the ongoing search for effective treatments for various diseases.
Latest Patents
Zoe holds a patent for "Oxepinopyrazole derivatives as inhibitors of P13-kinase activity." This invention is directed to compounds of formula (I) and their salts. The compounds developed by Zoe are specifically designed to inhibit PI3-kinase activity, which plays a vital role in cellular functions and disease progression.
Career Highlights
Zoe is currently employed at GlaxoSmithKline Intellectual Property Development Limited, where she continues to innovate and contribute to the pharmaceutical industry. Her expertise in kinase inhibitors has positioned her as a valuable asset in her field.
Collaborations
Zoe has collaborated with notable colleagues, including Andrew Baxter and Sophie Marie Bertrand. These partnerships have enhanced her research and development efforts, leading to advancements in therapeutic solutions.
Conclusion
Zoe Alicia Henley is a trailblazer in the field of kinase inhibition, with her innovative work paving the way for future medical advancements. Her contributions are essential in the fight against diseases influenced by kinase activity.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile